CoChat
Sign Up
Cited by 125Metal-Catalyzed Oxygenation MechanismsEnzyme Structure and FunctionProtein Structure and Dynamics

The crystal structure of human dopamine β-hydroxylase at 2.9 Å resolution

Open access
Vendelboe, Trine V., Harris, Pernille, Zhao, Yuguang, Walter, Thomas S., Harlos, Karl, El Omari, Kamel, Christensen, Hans E. M.·2016·Science Advances
DOI 10.1126/sciadv.1500980PMC PMC4846438
Open this paper in CoChat — free accountOpen PDF

Abstract

This first structure of the enzyme converting dopamine to norepinephrine provides new perspectives on numerous disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.1500980

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 57

  1. [1]Levin E. Y., Levenberg B., Kaufman S., The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J. Biol. Chem. 235, 2080– 2086 (1960). 14416204
  2. [3]Valentino R. J., Van Bockstaele E., Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur. J. Pharmacol. 583, 194– 203 (2008). 18255055 PMC2349983
  3. [4]Tully K., Bolshakov V. Y., Emotional enhancement of memory: How norepinephrine enables synaptic plasticity. Mol. Brain 3, 15 (2010). 20465834 PMC2877027
  4. [5]Lim S. S., Vos T., Flaxman A. D., Danaei G., Shibuya K., Adair-Rohani H., AlMazroa M. A., Amann M., Anderson H. R., Andrews K. G., Aryee M., Atkinson C., Bacchus L. J., Bahalim A. N., Balakrishnan K., Balmes J., Barker-Collo S., Baxter A., Bell M. L., Blore J. D., Blyth F., Bonner C., Borges G., Bourne R., Boussinesq M., Brauer M., Brooks P., Bruce N. G., Brunekreef B., Bryan-Hancock C., Bucello C., Buchbinder R., Bull F., Burnett R. T., Byers T. E., Calabria B., Carapetis J., Carnahan E., Chafe Z., Charlson F., Chen H., Chen J. S., Cheng A. T.-A., Child J. C., Cohen A., Colson K. E., Cowie B. C., Darby S., Darling S., Davis A., Degenhardt L., Dentener F., Des Jarlais D. C., Devries K., Dherani M., Ding E. L., Dorsey E. R., Driscoll T., Edmond K., Ali S. E., Engell R. E., Erwin P. J., Fahimi S., Falder G., Farzadfar F., Ferrari A., Finucane M. M., Flaxman S., Fowkes F. G. R., Freedman G., Freeman M. K., Gakidou E., Ghosh S., Giovannucci E., Gmel G., Graham K., Grainger R., Grant B., Gunnell D., Gutierrez H. R., Hall W., Hoek H. W., Hogan A., Hosgood H. D. III, Hoy D., Hu H., Hubbell B. J., Hutchings S. J., Ibeanusi S. E., Jacklyn G. L., Jasrasaria R., Jonas J. B., Kan H., Kanis J. A., Kassebaum N., Kawakami N., Khang Y.-H., Khatibzadeh S., Khoo J.-P., Kok C., Laden F., Lalloo R., Lan Q., Lathlean T., Leasher J. L., Leigh J., Li Y., Lin J. K., Lipshultz S. E., London S., Lozano R., Lu Y., Mak J., Malekzadeh R., Mallinger L., Marcenes W., March L., Marks R., Martin R., McGale P., McGrath J., Mehta S., Memish Z. A., Mensah G. A., Merriman T. R., Micha R., Michaud C., Mishra V., Mohd Hanafiah K., Mokdad A. A., Morawska L., Mozaffarian D., Murphy T., Naghavi M., Neal B., Nelson P. K., Nolla J. M., Norman R., Olives C., Omer S. B., Orchard J., Osborne R., Ostro B., Page A., Pandey K. D., Parry C. D. H., Passmore E., Patra J., Pearce N., Pelizzari P. M., Petzold M., Phillips M. R., Pope D., Pope C. A. III, Powles J., Rao M., Razavi H., Rehfuess E. A., Rehm J. T., Ritz B., Rivara F. P., Roberts T., Robinson C., Rodriguez-Portales J. A., Romieu I., Room R., Rosenfeld L. C., Roy A., Rushton L., Salomon J. A., Sampson U., Sanchez-Riera L., Sanman E., Sapkota A., Seedat S., Shi P., Shield K., Shivakoti R., Singh G. M., Sleet D. A., Smith E., Smith K. R., Stapelberg N. J. C., Steenland K., Stöckl H., Stovner L. J., Straif K., Straney L., Thurston G. D., Tran J. H., Van Dingenen R., van Donkelaar A., Veerman J. L., Vijayakumar L., Weintraub R., Weissman M. M., White R. A., Whiteford H., Wiersma S. T., Wilkinson J. D., Williams H. C., Williams W., Wilson N., Woolf A. D., Yip P., Zielinski J. M., Lopez A. D., Murray C. J., Ezzati M., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224– 2260 (2012). 23245609 PMC4156511
  5. [6]Grassi G., Seravalle G., Quarti-Trevano F., The 'neuroadrenergic hypothesis' in hypertension: Current evidence. Exp. Physiol. 95, 581– 586 (2010). 20008032
  6. [7]Trillo L., Das D., Hsieh W., Medina B., Moghadam S., Lin B., Dang V., Sanchez M. M., De Miguel Z., Ashford J. W., Salehi A., Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neurosci. Biobehav. Rev. 37, 1363– 1379 (2013). 23707776
  7. [8]Schroeder J. P., Epps S. A., Grice T. W., Weinshenker D., The selective dopamine β-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology 38, 1032– 1038 (2013). 23303068 PMC3629392
  8. [9]Cubells J. F., Zabetian C. P., Human genetics of plasma dopamine β-hydroxylase activity: Applications to research in psychiatry and neurology. Psychopharmacology 174, 463– 476 (2004). 15088079
  9. [10]Eipper B. A., Mains R. E., Glembotski C. C., Identification in pituitary tissue of a peptide α-amidation activity that acts on glycine-extended peptides and requires molecular oxygen, copper, and ascorbic acid. Proc. Natl. Acad. Sci. U.S.A. 80, 5144– 5148 (1983). 6576381 PMC384206
  10. [11]Prigge S. T., Kolhekar A. S., Eipper B. A., Mains R. E., Amzel L. M., Amidation of bioactive peptides: The structure of peptidylglycine α-hydroxylating monooxygenase. Science 278, 1300– 1305 (1997). 9360928
  11. [12]Xin X., Mains R. E., Eipper B. A., Monooxygenase X, a member of the copper-dependent monooxygenase family localized to the endoplasmic reticulum. J. Biol. Chem. 279, 48159– 48167 (2004). 15337741
  12. [13]Gray E. E., Small S. N., McGuirl M. A., Expression and characterization of recombinant tyramine β-monooxygenase from Drosophila: A monomeric copper-containing hydroxylase. Protein Expr. Purif. 47, 162– 170 (2006). 16376104
  13. [14]Iyer L. M., Anantharaman V., Aravind L., The DOMON domains are involved in heme and sugar recognition. Bioinformatics 23, 2660– 2664 (2007). 17878204
  14. [15]Stewart L. C., Klinman J. P., Dopamine beta-hydroxylase of adrenal chromaffin granules: Structure and function. Annu. Rev. Biochem. 57, 551– 592 (1988). 3052283
  15. [16]Kapoor A., Shandilya M., Kundu S., Structural insight of dopamine β-hydroxylase, a drug target for complex traits, and functional significance of exonic single nucleotide polymorphisms. PLOS One 6, e26509 (2011). 22028891 PMC3197665
  16. [17]Robertson J. G., Adams G. W., Medzihradszky K. F., Burlingame A. L., Villafranca J. J., Complete assignment of disulfide bonds in bovine dopamine β-hydroxylase. Biochemistry 33, 11563– 11575 (1994). 7918370
  17. [18]Wallace E. F., Krantz M. J., Lovenberg W., Dopamine-β-hydroxylase: A tetrameric glycoprotein. Proc. Nat. Acad. Sci. U.S.A. 70, 2253– 2255 (1973). PMC433712 4525162
  18. [19]Mangold J. B., Klinman J. P., Mechanism-based inactivation of dopamine β-monooxygenase by β-chlorophenethylamine. J. Biol. Chem. 259, 7772– 7779 (1984). 6547439
  19. [20]Ash D. E., Papadopoulos N. J., Colombo G., Villafranca J. J., Kinetic and spectroscopic studies of the interaction of copper with dopamine β-hydroxylase. J. Biol. Chem. 259, 3395– 3398 (1984). 6323422
  20. [21]Chen P., Bell J., Eipper B. A., Solomon E. I., Oxygen activation by the noncoupled binuclear copper site in peptidylglycine α-hydroxylating monooxygenase. Spectroscopic definition of the resting sites and the putative CuIIM–OOH intermediate. Biochemistry 43, 5735– 5747 (2004). 15134448
  21. [22]Brenner M. C., Klinman J. P., Correlation of copper valency with product formation in single turnovers of dopamine β-monooxygenase. Biochemistry 28, 4664– 4670 (1989). 2548587
  22. [23]Terland O., Flatmark T., Ascorbate as a natural constituent of chromaffin granules from the bovine adrenal medulla. FEBS Lett. 59, 52– 56 (1975). 1225621
  23. [24]Skotland T., Ljones T., Direct spectrophotometric detection of ascorbate free radical formed by dopamine β-monooxygenase and by ascorbate oxidase. Biochim. Biophys. Acta 630, 30– 35 (1980). 7388045
  24. [25]R. L. Osborne, J. P. Klinman, Insights into the proposed copper–oxygen intermediates that regulate the mechanism of reactions catalyzed by dopamine β-monooxygenase, peptidylglycine α-hydroxylating monooxygenase, and tyramine β-monooxygenase, in Copper-Oxygen Chemistry, K. D. Karlin, S. Itoh, Eds. (John Wiley & Sons Inc., Hoboken, NJ, 2011), pp. 1–22.
  25. [26]Solomon E. I., Heppner D. E., Johnston E. M., Ginsbach J. W., Cirera J., Qayyum M., Kieber-Emmons M. T., Kjaergaard C. H., Hadt R. G., Tian L., Copper active sites in biology. Chem. Rev. 114, 3659– 3853 (2014). 24588098 PMC4040215
  26. [27]Calabrese L., Carbonaro M., Musci G., Chicken ceruloplasmin. Evidence in support of a trinuclear cluster involving type 2 and 3 copper centers. J. Biol. Chem. 263, 6480– 6483 (1988). 2834379
  27. [28]Ducros V., Brzozowski A. M., Wilson K. S., Brown S. H., Østergaard P., Schneider P., Yaver D. S., Pedersen A. H., Davies G. J., Crystal structure of the type-2 Cu depleted laccase from Coprinus cinereus at 2.2 Å resolution. Nat. Struct. Biol. 5, 310– 316 (1998). 9546223
  28. [29]Kim C.-H., Zabetian C. P., Cubells J. F., Cho S., Biaggioni I., Cohen B. M., Robertson D., Kim K.-S., Mutations in the dopamine β-hydroxylase gene are associated with human norepinephrine deficiency. Am. J. Med. Genet. 108, 140– 147 (2002). 11857564
  29. [30]Tang Y., Buxbaum S. G., Waldman I., Anderson G. M., Zabetian C. P., Köhnke M. D., Cubells J. F., A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine β-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biol. Psychiatry 60, 1034– 1038 (2006). 16616730
  30. [31]Comings D. E., Wu S., Chiu C., Ring R. H., Gade R., Ahn C., MacMurray J. P., Dietz G., Muhleman D., Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: The additive and subtractive effect of the three dopaminergic genes—DRD2, DβH, and DAT1. Am. J. Med. Genet. 67, 264– 288 (1996). 8725745
  31. [32]Lieberman A. N., Freedman L. S., Goldstein M., Serum dopamine-β-hydroxylase activity in patients with Huntington’s chorea and Parkinson’s disease. Lancet 299, 153– 154 (1972). 4109012
  32. [33]Togsverd M., Werge T. M., Tankó L. B., Bagger Y. Z., Hansen T., Qin G., Christiansen C., Rasmussen H. B., Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J. Affect. Disord. 106, 169– 172 (2008). 17698206
  33. [35]Zabetian C. P., Anderson G. M., Buxbaum S. G., Elston R. C., Ichinose H., Nagatsu T., Kim K.-S., Kim C.-H., Malison R. T., Gelernter J., Cubells J. F., A quantitative-trait analysis of human plasma–dopamine β-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 68, 515– 522 (2001). 11170900 PMC1235285
  34. [36]Almeida L., Nunes T., Costa R., Rocha J. F., Vaz-da-Silva M., Soares-da-Silva P., Etamicastat, a novel dopamine β-hydroxylase inhibitor: Tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin. Ther. 35, 1983– 1996 (2013). 24296323
  35. [37]Reeves P. J., Callewaert N., Contreras R., Khorana H. G., Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. U.S.A. 99, 13419– 13424 (2002). 12370423 PMC129688
  36. [38]Frigon R. P., Stone R. A., Human plasma dopamine beta-hydroxylase. Purification and properties. J. Biol. Chem. 253, 6780– 6786 (1978). 567644
  37. [39]Li B., Tsing S., Kosaka A. H., Nguyen B., Osen E. G., Bach C., Chan H., Expression of human dopamine β-hydroxylase in drosophila Schneider 2 cells. Biochem. J. 313, 57– 64 (1996). 8546710 PMC1216909
  38. [40]Saxena A., Hensley P., Osborne J. C. Jr, Fleming P. J., The pH-dependent subunit dissociation and catalytic activity of bovine dopamine β-hydroxylase. J. Biol. Chem. 260, 3386– 3392 (1985). 3972830
  39. [41]Zhu H., Sommerhalter M., Nguy A. K. L., Klinman J. P., Solvent and temperature probes of the long-range electron-transfer step in tyramine β-monooxygenase: Demonstration of a long-range proton-coupled electron-transfer mechanism. J. Am. Chem. Soc. 137, 5720– 5729 (2015). 25919134 PMC4970857
  40. [42]Ramsden C. A., Riley P. A., Tyrosinase: The four oxidation states of the active site and their relevance to enzymatic activation, oxidation and inactivation. Bioorg. Med. Chem. 22, 2388– 2395 (2014). 24656803
  41. [43]Klabunde T., Eicken C., Sacchettini J. C., Krebs B., Crystal structure of a plant catechol oxidase containing a dicopper center. Nat. Struct. Biol. 5, 1084– 1090 (1998). 9846879
  42. [44]Klotz I. M., Klotz T. A., Oxygen-carrying proteins: A comparison of the oxygenation reaction in hemocyanin and hemerythrin with that in hemoglobin. Science 121, 477– 480 (1955). 14372954
  43. [45]Lazdunski M., Petitclerc C., Chappelet D., Lazdunski C., Flip-flop mechanisms in enzymology. A model: The alkaline phosphatase of Escherichia coli. Eur. J. Biochem. 20, 124– 139 (1971). 4325354
  44. [46]Ferris H. U., Coles M., Lupas A. N., Hartmann M. D., Crystallographic snapshot of the Escherichia coli EnvZ histidine kinase in an active conformation. J. Struct. Biol. 186, 376– 379 (2014). 24681325
  45. [47]Aricescu A. R., Lu W., Jones E. Y., A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Cryst. D62, 1243– 1250 (2006). 17001101
  46. [48]Zhao Y., Bishop B., Clay J. E., Lu W., Jones M., Daenke S., Siebold C., Stuart D. I., Jones E. Y., Aricescu A. R., Automation of large scale transient protein expression in mammalian cells. J. Struct. Biol. 175, 209– 215 (2011). 21571074 PMC3477309
  47. [49]Walter T. S., Diprose J. M., Mayo C. J., Siebold C., Pickford M. G., Carter L., Sutton G. C., Berrow N. S., Brown J., Berry I. M., Stewart-Jones G. B. E., Grimes J. M., Stammers D. K., Esnouf R. M., Jones E. Y., Owens R. J., Stuart D. I., Harlos K., A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta Cryst. D61, 651– 657 (2005). PMC7159505 15930615
  48. [53]Vonrhein C., Blanc E., Roversi P., Bricogne G., Automated structure solution with autoSHARP. Methods Mol. Biol. 364, 215– 230 (2007). 17172768
  49. [54]Prigge S. T., Kolhekar A. S., Eipper B. A., Mains R. E., Amzel L. M., Substrate-mediated electron transfer in peptidylglycine α-hydroxylating monooxygenase. Nat. Struct. Biol. 6, 976– 983 (1999). 10504734
  50. [56]Winn M. D., Ballard C. C., Cowtan K. D., Dodson E. J., Emsley P., Evans P. R., Keegan R. M., Krissinel E. B., Leslie A. G. W., McCoy A., McNicholas S. J., Murshudov G. N., Pannu N. S., Potterton E. A., Powell H. R., Read R. J., Vagin A., Wilson K. S., Overview of the CCP4 suite and current developments. Acta Cryst. D67, 235– 242 (2011). PMC3069738 21460441
  51. [57]Adams P. D., Afonine P. V., Bunkóczi G., Chen V. B., Davis I. W., Echols N., Headd J. J., Hung L.-W., Kapral G. J., Grosse-Kunstleve R. W., McCoy A. J., Moriarty N. W., Oeffner R., Read R. J., Richardson D. C., Richardson J. S., Terwilliger T. C., Zwart P. H., PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Cryst. D66, 213– 221 (2010). PMC2815670 20124702
  52. [58]Murshudov G. N., Vagin A. A., Dodson E. J., Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst. D53, 240– 255 (1997). 15299926
  53. [60]Chen V. B., Arendall W. B. III, Headd J. J., Keedy D. A., Immormino R. M., Kapral G. J., Murray L. W., Richardson J. S., Richardson D. C., MolProbity: All-atom structure validation for macromolecular crystallography. Acta Cryst. D66, 12– 21 (2010). PMC2803126 20057044
  54. [62]Sievers F., Wilm A., Dineen D., Gibson T. J., Karplus K., Li W., Lopez R., McWilliam H., Remmert M., Söding J., Thompson J. D., Higgins D. G., Fast, scalable generation of high-quality protein multiple sequence alignments using clustal omega. Mol. Syst. Biol. 7, 539 (2011). 21988835 PMC3261699
  55. [63]Holm L., Rosenström P., Dali server: Conservation mapping in 3D. Nucl. Acids Res. 38, W545– W549 (2010). 20457744 PMC2896194
  56. [65]Zheng H., Chordia M. D., Cooper D. R., Chruszcz M., Müller P., Sheldrick G. M., Minor W., Validation of metal-binding sites in macromolecular structures with the CheckMyMetal web server. Nat. Protoc. 9, 156– 170 (2014). 24356774 PMC4410975
  57. [66]Chovancova E., Pavelka A., Benes P., Strnad O., Brezovsky J., Kozlikova B., Gora A., Sustr V., Klvana M., Medek P., Biedermannova L., Sochor J., Damborsky J., CAVER 3.0: A tool for the analysis of transport pathways in dynamic protein structures. PLOS Comput. Biol. 8, e1002708 (2012). 23093919 PMC3475669

Cited by

Sorted by citations

Authors
Vendelboe, T. V., Harris, P., Zhao, Y., Walter, T. S., Harlos, K., El Omari, K., & Christensen, H. E. M.
Affiliations
  • Technical University of Denmark (DK)
  • Centre for Human Genetics (GB)
  • Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Corresponding author
Christensen, Hans E. M.
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2016-04
Volume
2
Issue
4
Pages
e1500980-e1500980
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.1500980
PMC
PMC4846438
OpenAlex
W2322161127
Cited by
125
References
1
Citations by year
2026: 12 · 2025: 18 · 2024: 15 · 2023: 11 · 2022: 14 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 7 · 2017: 9 · 2016: 8
FWCI
4.73
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, cc-by)
Funders
  • Wellcome Trust (075491, 075491/Z/04,)
  • Diamond Light Source
  • European Commission
  • DanScatt
  • Forsknings- og Innovationsstyrelsen
  • Medical Research Council (MR/N00065X/1)
  • Danish Agency for Science and Higher Education
Topics
  • Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
  • Physical Sciences › Materials Science › Materials Chemistry › Enzyme Structure and Function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
dopamine beta-hydroxylase, crystal structure, norepinephrine synthesis, copper binding site, active site conformation, dimerization domain, peptidylglycine alpha-hydroxylating monooxygenase
MeSH terms
Binding Sites, Copper, Dopamine, Dopamine beta-Hydroxylase, Humans, Norepinephrine, Protein Conformation, Crystallography, X-Ray, Catalytic Domain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review